Compare Eli Lilly And Co (LLY) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Texas Instruments Incorporated — how do they compare? Eli Lilly And Co trades at $1,175.96 (market cap $1.02T), while Texas Instruments Incorporated trades at $291.3 (market cap $258.53B). The key difference: Eli Lilly And Co is far larger — about 3.9× Texas Instruments Incorporated's market cap, and Texas Instruments Incorporated pays the higher dividend (2%). Which is the better fit depends on your goals.
| LLY | TXN | |
|---|---|---|
Market Cap | $1.02T | $258.53B |
Sector | Health | Technology |
52-Week High | $1.24K | $332.35 |
52-Week Low | $625.65 | $153.33 |
Enterprise Value | $1.06T | $267.48B |
Dividend Yield | 0.6% | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
Texas Instruments (TXN) trades at $284.02, down 2.47% over 24 hours, with technical signals leaning bearish. The company reported mixed recent earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue and net income have shown volatility, with 2025 figures at $17.68B and $5.00B respectively. Analysts maintain a consensus Buy rating with a $313.05 price target, indicating potential upside. Recent CFO transition news and AI-driven demand in data centers are key developments.
Outlook remains cautiously optimistic given strong profitability margins and analyst support, but risks include elevated valuation multiples and competitive pressures in the semiconductor sector. The stock's current price near support at $281 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
